| Q92314206 | A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease |
| Q54933580 | A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease. |
| Q52595193 | A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. |
| Q50220919 | Abnormal Barrier Function in Gastrointestinal Disorders. |
| Q64081407 | An Update on Interleukin-9: From Its Cellular Source and Signal Transduction to Its Role in Immunopathogenesis |
| Q47969652 | Animal models for studying epithelial barriers in neonatal necrotizing enterocolitis, inflammatory bowel disease and colorectal cancer. |
| Q55236940 | Cell-Intrinsic Roles for Autophagy in Modulating CD4 T Cell Functions. |
| Q39189861 | Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms |
| Q92447462 | Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD |
| Q55176161 | Effector T Helper Cell Subsets in Inflammatory Bowel Diseases. |
| Q39102508 | Gut permeability and mucosal inflammation: bad, good or context dependent. |
| Q92259788 | Helicobacter pylori Deregulates T and B Cell Signaling to Trigger Immune Evasion |
| Q38815064 | Helminths and intestinal barrier function |
| Q94484029 | IL-33/ST2/IL-9/IL-9R signaling disrupts ocular surface barrier in allergic inflammation |
| Q40058815 | IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation. |
| Q52658494 | IL-9 Signaling Pathway: An Update. |
| Q55006446 | IL-9 and Mast Cells Are Key Players of Candida albicans Commensalism and Pathogenesis in the Gut. |
| Q90043719 | IL-9 exerts biological function on antigen-experienced murine T cells and exacerbates colitis induced by adoptive transfer |
| Q58108127 | IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling |
| Q55259683 | Intraperitoneal administration of the anti-IL-23 antibody prevents the establishment of intestinal nematodes in mice. |
| Q39391736 | Introduction for the special issue on "Tissue Barriers in Inflammation". |
| Q90320869 | Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More |
| Q48351328 | Old and New Lymphocyte Players in Inflammatory Bowel Disease |
| Q38665573 | Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders |
| Q41701341 | Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells |
| Q33628862 | Self-adjuvanting C18 lipid vinil sulfone-PP2A vaccine: study of the induced immunomodulation against Trichuris muris infection |
| Q53718821 | Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease. |
| Q33805888 | Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis |
| Q37688655 | TH9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer. |
| Q40224209 | Th9 Cells: New Member of T Helper Cell Family. |
| Q39006003 | Th9 cells in inflammatory bowel diseases |
| Q40099296 | The Microbiome Activates CD4 T-cell-mediated Immunity to Compensate for Increased Intestinal Permeability |
| Q92188877 | To Be or Not to Be a Pathogen: Candida albicans and Celiac Disease |